Immunogen comprising an HIV envelope protein, a ligand and...

Details Immunogen comprising an HIV envelope protein, a ligand and... Immunogen comprising an HIV envelope protein, a ligand and...

2006-04-25

2006-04-25

Stucker, Jeffrey (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S185100, C424S188100, C424S193100, C424S194100, C424S208100, C530S324000, C530S325000, C530S326000, C530S327000, C530S388350, C530S389400, C530S391100, C530S826000

Reexamination Certificate

active

07033593

ABSTRACT:
The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.

REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5518723 (1996-05-01), DeVico et al.
patent: 5843454 (1998-12-01), Devico et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2002/0086283 (2002-07-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0001851 (2004-01-01), Haynes et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 2004/0086506 (2004-05-01), Haynes et al.
patent: 2004/0197344 (2004-10-01), Haynes et al.
patent: WO 93/15750 (1993-08-01), None
patent: WO 94/15638 (1994-07-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 00/08043 (2000-02-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/024149 (2002-03-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004/009785 (2004-01-01), None
patent: WO 2004/075850 (2004-09-01), None
patent: WO 2005/016952 (2005-02-01), None
patent: WO 2005/028625 (2005-03-01), None
Fahey et al. AStatus of immune-based therapies in HIV infection and AIDS@, Clinical and Experimental Immunology, vol. 88 (1992), pp. 1-5.
Fox “No winners against AIDS”, Bio/Technology, vol. 12 (Feb. 1994), p. 128.
Paul Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), p. 1387.
Stamatatos et al, “Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates”, AIDS Research and Human Retroviruses 16(10):981-994 (2000).
Hoffman et al, “Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein”, Proc. Natl. Acad. Sci. USA 96:6359-6364 (1999).
Golding et al, “Phorbol Ester-Induced Down Modulation of Tailless CD4 Receptors Requires Prior Binding of gp120 and Suggests a Role for Accessory Molecules”, Journal of Virology 69(10):6140-6148 (1995).
Kwong et al, “Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody”, Nature 393:648-659 (1998).
Wyatt et al, “Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Immunodeficiency Virus Type 1 gp120 Epitopes Induced by Receptor Binding”, Journal of Virology 69(9):5723-5733 (1995).
Furata et al, “Capture of an early fusion-active conformation of HIV-1 gp41”, Nature Struct. Biol. 5:276 (1998).
LaCasse et al, “Fusion-Competent Vaccines” Broad Neutralization of Primary Isolates of HIV, Science 283:357 (1997).
Boots et al, “Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries”, AIDS Research and Human Retroviruses 13(18):1549-1559 (1997).
Bieniasz et al, “HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor”, The EMBO Journal 16(10):2599-2609 (1997).
Wild et al, “Prospensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex”, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994).
Collman et al, “An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1”, Journal of Virology 66(12):7517-7521 (1992).
Alam et al, “T-cell-receptor affinity and thymocyte positive selection”, Letters to Nature 381:616-620 (1996).
O'Shannessy et al, “Immobilization Chemistries Suitable for Use in the BIAcore Surface Plasmon Resonance Detector”, Analytical Biochemistry 205:132-136 (1992).
Mascola et al, “Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type I”, Infect. Dis. 173:340-348 (1996).
Rizzuto et al, “A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding”, Science 280:1949-1953 (1998).
Trkola et al, “Human Monoclonal Antibody 2G12 Defines a Distinctive Neutralization Epitope on the gp120 Glycoprotein of Human Immunodeficiency Virus Type 1”, Journal of Virology 70(2):1100-1108 (1996).
Mo et al, “Human Immunodeficiency Virus Type 1 Mutants That Escape Neutralization by Human Monoclonal Antibody lgG1b12”, Journal of Virology 71(9):6869-6874 (1997).
Ye et al, “Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo”, Journal of Virology 74(24):11955-11962 (2000).
Fouts et al, “Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligometric Form of the Envelope Glycoprotein Complex”, Journal of Virology 71(4):2779-2785 (1997).
Sullivan et al, “CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization”, Journal of Virology 72(6):4694-4703 (1998).
Moore et al, “Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies”, Journal of Virology 68(12):8350-8364 (1994)—Abstract.
Jiang et al, “A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein”, Journal of Virology 72(12):10213-10217 (1998).
Rimsky et al, “Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides”, Journal of Virology 72(2):986-993 (1998).
Earl et al, “Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140”, Journal of Virology 75(2):645-653 (2001).
Muster et al, “A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1”, Journal of Virology 67(11):6642-6647 (1993)—Abstract.
Cormier et al, “Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120”, PNAS 97(11):5762-5767 (2000).
Hoffman et al, “A biosensor assay for studying ligand-membrane receptor interactions: Binding of antibodies and HIV-1 Env to chemokine receptors”, PNAS 97(21):11215-11220 (2000).
Myszka et al, “Energetics of the HIV gp120-CD4 binding reaction”, PNS 97(16):9026-9031 (2000).
Roben et al, “Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1”, Journal of Virology 68(8):4821-4828 (1994)—Abstract.
Muster et al, “Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS”, Journal of Virology 68(6):4031-4034 (1994)—Abstract.
Earl et al, “Native oligomeric human immunodeficiency virust type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities”, Journal of Virology 68(5):3015-3026 (1994)—Abstract.

Affiliated with

Also associated with

Rating

Immunogen comprising an HIV envelope protein, a ligand and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogen comprising an HIV envelope protein, a ligand and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogen comprising an HIV envelope protein, a ligand and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3616893